Are you "Profiting from the Pros?"
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.
If you wish to go to ZacksTrade, click
OK. If you do not, click Cancel.
Back to top
AMAG Pharmaceuticals ( AMAG - Analyst Report) announced its preliminary fourth quarter and full year 2013 financial results. AMAG’s shares gained more than 9.3% following the announcement. Q4 Snapshot
AMAG’s total revenues for the fourth quarter of 2013 are expected within $21.3–$21.8 million, compared with $21.1 million in the year-ago period. The company’s projected range is above the Zacks Consensus Estimate of $21 million. AMAG’s fourth quarter revenues include U.S. net Feraheme product revenues of $18.6–$19.1 million, compared with $14.4 million in the year-ago period.
AMAG records revenues mainly from Feraheme, an injectable drug for intravenous use as iron replacement therapy for the treatment of iron deficiency anemia (IDA) in adults suffering from chronic kidney disease (CKD). AMAG is looking to get Feraheme’s label expanded for the treatment of IDA in all adults suffering from CKD with a history of unsuccessful oral iron therapy. The FDA is expected to render a final decision on Feraheme’s label expansion by Jan 21, 2014. 2013 Guidance
The company’s total revenue for 2013 is expected to be in the band of $80.5–$81 million, compared with the year-ago figure of $85.4 million. The Zacks Consensus Estimate of $81 million is on the high end of the company’s guidance.
Meanwhile, the company’s U.S. net Feraheme revenues look impressive. AMAG expects U.S. net Feraheme product revenues in the range of $71−$71.5 million, up from the 2012 figure of $58.3 million. Higher volume and improved pricing drove 2013 Feraheme sales.
AMAG expects 2013 operating expenses within $79.5–$81 million, down about 7% from 2012. Our Take
AMAG’s fourth quarter and full year 2013 Feraheme sales figures look impressive. However, we believe investor focus will stay on the upcoming FDA decision on Feraheme’s label expansion. We expect a negative decision or further delay in the approval of the broader label of Feraheme. This will have a negative impact on AMAG’s share price.
AMAG currently carries a Zacks Rank #4 (Sell). Some better-ranked stocks include Jazz Pharmaceuticals Public Limited Company ( JAZZ - Analyst Report) , Actelion Ltd. ( ALIOF - Snapshot Report) and Gentium . All the stocks hold a Zacks Rank #1 (Strong Buy).